Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
14.69 USD +2.08% Intraday chart for CVRx, Inc. -1.41% -53.28%
Sales 2024 * 54.89M 74.97M Sales 2025 * 76.74M 105M Capitalization 317M 433M
Net income 2024 * -41M -55.99M Net income 2025 * -34M -46.43M EV / Sales 2024 * 5.1 x
Net cash position 2024 * 37.11M 50.68M Net cash position 2025 * 12.66M 17.29M EV / Sales 2025 * 3.97 x
P/E ratio 2024 *
-7.51 x
P/E ratio 2025 *
-9.45 x
Employees 200
Yield 2024 *
-
Yield 2025 *
-
Free-Float 84.12%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.08%
1 week-1.41%
Current month-19.33%
1 month-19.33%
3 months-46.05%
6 months+11.71%
Current year-53.28%
More quotes
1 week
13.57
Extreme 13.57
14.87
1 month
13.57
Extreme 13.57
19.24
Current year
13.57
Extreme 13.57
32.43
1 year
9.92
Extreme 9.9201
33.14
3 years
4.60
Extreme 4.6
33.14
5 years
4.60
Extreme 4.6
33.14
10 years
4.60
Extreme 4.6
33.14
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 22-12-20
Director of Finance/CFO 41 15-07-31
Chief Operating Officer - 06-06-30
Members of the board TitleAgeSince
Director/Board Member 59 08-09-30
Director/Board Member 50 20-06-30
Director/Board Member 55 20-06-30
More insiders
Date Price Change Volume
24-04-26 14.69 +2.08% 86,218
24-04-25 14.39 -0.07% 141,179
24-04-24 14.4 +0.77% 119,882
24-04-23 14.29 -2.72% 118,473
24-04-22 14.69 -1.41% 150,658

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm

More quotes
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.69 USD
Average target price
34 USD
Spread / Average Target
+131.45%
Consensus